Metraipolis › archive › dc_da310cb977dc

Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer — Europe PMC PMID:41930297

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41930297
DOI
10.1016/j.esmorw.2026.100685
License (as archived)
solo-consultazione
Archived
2026-10-08T16:05:51.689Z
SHA-256 of the archived text
fc89f2de1f19f965e74f938af74bbfcd2ebf83676a226ab033dd26d168d62d91
Stable URL of this page
https://metraipolis.com/documento/dc_da310cb977dc

How to cite

Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer — Europe PMC PMID:41930297 — Europe PMC (en), https://europepmc.org/article/MED/41930297 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da310cb977dc (Metraipolis archive dc_da310cb977dc, sha256 fc89f2de1f19f965e74f938af74bbfcd2ebf83676a226ab033dd26d168d62d91)
BibTeX
@misc{dcda310cb977dc,
  title = {Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer — Europe PMC PMID:41930297},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41930297},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da310cb977dc; sha256 fc89f2de1f19f965e74f938af74bbfcd2ebf83676a226ab033dd26d168d62d91},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41930297. Agents can read the archived copy with the MCP tool read_document.